Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.  

Despite trial miss, Novartis still believes in Entresto for ...

Entresto tops mainstay ACE inhibitor in heart failure trial

Two years ago, Novartis launched a big trials programme for its heart failure drug Entresto in the hope of revving up disappointing initial sales, and one of those trials has just delivered positiv

The biggest pharma stories of 2016 so far

The top 10 pharma milestones of the year to date.

Novartis ramping up investment in new drugs

Swiss pharma loses patent on key cancer drug

10 drugs – and their prices – which changed pharma in 2015

In a record-breaking year for pharma, which drugs were the most outstanding?